Streetbeat News

Earnings

SMHI

Seacor Marine Holdings (SMHI) reported Q4 earnings of $0.20 per share, surpassing the consensus estimate of $(0.49) by 140.82%. Sales reached $73.08M, beating estimates of $63.55M by 15%. This marks a significant improvement from the previous year, with a 140% increase in earnings and a 26.17% increase in sales.

Portfolio Pulse from Happy Mohamed

February 29, 2024 | 10:10 pm

REAL

TheRealReal projects its FY24 revenue to be in the range of $580 million to $605 million, which is in line with the analyst estimate of $581.701 million.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:09 pm

REAL

TheRealReal projects its Q1 2024 revenue to be between $135M and $145M, which is below the estimated $143.201M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:09 pm

RPAY

REPAY projects its full-year 2024 revenue to be between $314M and $320M, closely aligning with the estimated $318.98M. The company anticipates its Adjusted EBITDA to increase at a faster rate than gross profit and plans to cut capital expenditures to boost cash conversion.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:08 pm

SEER

Seer, a company specializing in proteomics technology, forecasts its FY24 revenue to be in the range of $18M-$20M, which is around the analyst estimate of $19.801M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:05 pm

DNA

Ginkgo Bioworks anticipates adding 100-120 new cell programs to its cell engineering platform in 2024, with expected total revenue ranging between $215M-$235M, which is below the estimated $279.546M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:04 pm

CRDF

Cardiff Oncology's shares surged following the announcement of favorable Q4 financial outcomes, a positive update on the Phase 2 ONSEMBLE trial for RAS-mutated mCRC, and the initiation of dosing in a first-line RAS-mutated mCRC trial.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:03 pm

DNA

Ginkgo Bioworks Holdings (NYSE:DNA) reported Q4 earnings with a loss of $(0.11) per share, missing the $(0.10) estimate, and sales of $34.76M, missing the $42.50M estimate. This represents a 10% increase in losses and an 18.22% miss in sales estimates compared to the same period last year, alongside a 64.64% decrease in sales from $98.28M.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:02 pm

FSR

Fisker (NYSE:FSR) reported Q4 2023 earnings with a GAAP EPS of $(1.230), significantly missing the $(0.170) estimate. Sales were $200.100M, also missing the expected $310.795M. Despite this, sales increased by 65.29K% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:00 pm

CCIF

Carlyle Credit Income Fund (CCIF) reported a Q1 2024 net investment income of $0.24 per share, a significant increase from a loss of $0.14 per share in the previous quarter.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 10:00 pm